AUSTIN, Texas - Genprex , Inc. (NASDAQ: NASDAQ:GNPX), a clinical-stage gene therapy company, announced positive preclinical results for its lead drug candidate, Reqorsa® Gene Therapy, at the recent EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The event, which took place from October 23-25, 2024, in Barcelona, Spain, saw Genprex's research collaborators present findings on Reqorsa's potential in treating various forms of cancer resistant to other therapies.
The presented studies focused on the effectiveness of Reqorsa in combating KRAS G12C mutant lung cancer, mesothelioma, and glioblastoma, cancers known for their resistance to existing treatments. Genprex's CEO, Ryan Confer, expressed optimism about the data, highlighting the established role of the TUSC2 gene in lung cancer and the expansion of Reqorsa's use for other cancer indications.
Following these presentations, Genprex has filed two provisional patent applications related to the use of Reqorsa in treating mesothelioma and glioblastoma. These filings are in partnership with the respective institutions involved in the research.
Reqorsa consists of a plasmid with the TUSC2 gene encapsulated in non-viral lipid nanoparticles, which is designed to target cancer cells specifically while minimizing impact on normal tissue. This therapy is part of Genprex's Oncoprex® Delivery System and is administered intravenously. Laboratory studies have shown a significantly higher uptake of TUSC2 in tumor cells compared to normal cells after treatment with Reqorsa.
Genprex's ongoing clinical trials are evaluating Reqorsa for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with both programs having received Fast Track Designation from the FDA. Additionally, the SCLC program has been granted an FDA Orphan Drug Designation.
The company's broader mission includes developing gene therapies for large patient populations with cancer and diabetes who have limited treatment options. Genprex continues to work with world-class institutions to advance its pipeline of gene therapies.
This report is based on a press release statement from Genprex, Inc. and does not include any additional analysis or opinion.
In other recent news, Genprex, Inc. has made significant strides in its gene therapy research. The company has initiated a collaboration with the University of Michigan Rogel Cancer Center and the non-profit group ALK Positive to study potential treatments for ALK-EML4 positive translocated lung cancer. The research focuses on the TUSC2 gene and its potential in combination with ALK-inhibitors.
Genprex has also reported progress in its Acclaim-1 and Acclaim-3 clinical trials for lung cancer treatments. The Acclaim-1 trial has reported prolonged progression-free survival in two patients, while the Acclaim-3 trial has noted a partial remission in the first treated patient. The company has also formed a Mesothelioma Clinical Advisory Board to enhance its research efforts in treating mesothelioma.
Despite facing potential delisting from Nasdaq due to a failure to meet the minimum bid price requirement, Genprex continues to advance its pharmaceutical preparations in the biotechnology sector. The analyst firm H.C. Wainwright has initiated coverage of Genprex's stock with a Buy rating. In another strategic move, Genprex has announced plans to spin off its diabetes gene therapy program into a new subsidiary, NewCo, to focus on the development of GPX-002, a gene therapy drug candidate for Type 1 and Type 2 diabetes. These recent developments highlight Genprex's ongoing commitment to advancing gene therapies for large patient populations with limited treatment options.
InvestingPro Insights
Genprex's recent positive preclinical results for Reqorsa® Gene Therapy are reflected in the company's recent market performance. According to InvestingPro data, Genprex has seen a significant return of 31.13% over the last week and an impressive 433.69% over the last month. This surge in stock price aligns with the optimism surrounding the company's recent announcements at the EORTC-NCI-AACR Symposium.
However, investors should approach with caution. An InvestingPro Tip notes that Genprex's stock generally trades with high price volatility, which is evident in its recent price movements. Additionally, the company is not profitable over the last twelve months, with an adjusted operating income of -$26.29 million USD for the same period.
Despite these challenges, another InvestingPro Tip highlights that Genprex holds more cash than debt on its balance sheet, potentially providing financial flexibility as it continues its clinical trials and research efforts.
For those considering an investment in Genprex, it's worth noting that InvestingPro offers 10 additional tips that could provide further insights into the company's financial health and market position. These additional tips could be particularly valuable given the complex nature of the biotechnology sector and Genprex's ongoing clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.